Skip Navigation



Hum. Reprod. Advance Access published online on April 22, 2004
Human Reproduction, doi:10.1093/humrep/deh250
© 2004 by European Society of Human Reproduction and Embryology
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/6/1465    most recent
deh250v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fernandez, H.
Right arrow Articles by Roux, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fernandez, H.
Right arrow Articles by Roux, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received April 25, 2003
Accepted March 16, 2004

Article

One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial

H. Fernandez 1*, C. Lucas 2, B. Hédon 3, J.L. Meyer 4, J.M. Mayenga 5, C. Roux 6

1 Service de Gynécologie-Obstétrique, Hôpital Antoine Béclère, AP-HP, 92141 Clamart, France
2 Laboratoires Takeda, 92816 Puteaux, France
3 Service de Gynécologie-Obstétrique, Hôpital Universitaire Arnaud de Villeneuve, 34295 Montpellier, France
4 Beaumont Clinic, 63110 Beaumont, France
5 Service de Gynécologie-Obstétrique, Hôpital Jean Rostand, 92311 Sèvres, France
6 Service de Rhumatologie, Hôpital Cochin, Université René-Descartes, 75014 Paris, France

* To whom correspondence should be addressed. E-mail: herve.fernandez{at}abc.ap-hop-paris.fr.


  Abstract

BACKGROUND: It has been proposed that hormonal supplementation during prolonged GnRH agonist therapy prevents hypoestrogenic side effects, including bone loss. The optimal combination for long-term treatments with safe metabolic profile remains questionable. A norprogesterone derivative, promegestone, was assessed for the first time in a double-blind trial. METHODS: Seventy-eight patients with endometriosis with rAFS (Revised American Society for Reproductive Medicine) scores of III-IV were randomly assigned to monthly leuprorelin 3.75 mg (1 year) which, after the third injection was used in combination with promegestone 0.5 mg (P) plus either estradiol placebo (PL) or estradiol 2 mg (E) per day. Bone mineral density (BMD) was determined at baseline, 6 and 12 months, and biological and clinical quarterly assessments were performed. Analysis was by the intention to treat method. RESULTS: At month 12, BMD changes from baseline were -6.1 ± 3.7 and -4.9 ± 4.0% in the PL-P group, at the spine and hip, respectively. This bone loss was prevented in the E-P group: -1.9 ± 3.1 and -1.4 ± 2.3%, respectively (P < 0.0001 inter-group comparisons). The BMD decrease in the E-P group was explained by the changes occurring during the first 6 months of treatment. There was no deleterious change in lipid parameters. Clinical improvement was observed without an inter-group difference. CONCLUSIONS: Estradiol 2 mg and promegestone 0.5 mg per day is an effective and safe add-back therapy, which can be proposed for prolonged leuprorelin treatment over 6 months in severe endometriosis.

Key words: Key words: add-back therapy/bone mineral density/endometriosis/GnRH agonists/leuprorelin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.